Biopharmaceutical/Cell Therapy - CAR-T and Engineered T Cell Therapeutics
Strategic Profile
The company achieved a successful US launch of its lead product AUCATZYL with full year 2025 sales well above expectations and more than 60 treatment centers offering the therapy, while establishing reliable, high-quality product delivery with consistent turnaround time. AUCATZYL received regulatory approval from the FDA, EMA and MHRA for adult r/r B-ALL and launched commercially in the US and UK in 2025, positioning Autolus for expansion into autoimmune indications.
Cyborg Score Rationale
The company reported 2025 revenue of $75 million with 2026 guidance of $120-$135 million, representing 80-129% revenue growth accelerating faster than the 60% historical growth rate. However, the company previously reported negative gross margin and must execute manufacturing changes to achieve positive margin in 2026. Pipeline expansion into lupus and MS shows promise but execution risk remains.
Top Insights
Q4 2025 product revenue reached approximately $24 million, achieving approximately $75 million for full year 2025 in first commercial year.
CARLYSLE trial data show encouraging DORIS responses and immune reset in lupus patients; 50M cell dose selected as recommended Phase 2 dose with Phase 2 trial design aligned with FDA for lupus nephritis registrational path.
Analysts forecast 2026 revenue of $144.3 million, a 182% improvement versus prior 12 months, with earnings losses predicted to shrink substantially.
In January 2026, company announced evaluation of Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications.
Named Competitors
Yescarta/Yescarta 2 — Commercial-stage CAR-T therapy for hematologic malignancies
Tecartus — CAR-T therapy for mantle cell lymphoma
Kymriah — Commercial CAR-T therapy for leukemia and lymphoma
Recent Developments
(February 2026) Inducement stock option grants announced under Nasdaq rules for new employee hiring
(January 2026) Announced partnership with Cellares to evaluate automated cell manufacturing platform for scalability
(January 2026) Reported $75M 2025 revenue, $120-$135M 2026 guidance; UK and EU approvals secured for AUCATZYL
(December 2025) Presented Phase 1 CARLYSLE trial data at ASH Annual Meeting showing deep B-cell responses in lupus patients
Open the full interactive Autolus Therapeutics plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.